ストックスクリーナーアプリを入手
297.02
2.48%
-7.56
プレマーケット:
294.63
-2.39
-0.80%
Praxis Precision Medicines Inc (PRAX) 最新ニュース
Praxis Precision Medicines stock gains as TD Cowen reiterates Buy on FDA breakthrough status - Investing.com India
Praxis: Priced For Perfection Heading Into 2026 (NASDAQ:PRAX) - Seeking Alpha
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug - ts2.tech
Praxis Precision Medicines stock gets FDA boost as H.C. Wainwright maintains Buy - Investing.com Canada
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.4%Here's Why - MarketBeat
Praxis Precision (PRAX) Shares Drop Amid Market Movement - GuruFocus
Truist Securities reiterates Buy rating on Praxis Precision Medicines stock - Investing.com India
Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide - Yahoo Finance
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target - ts2.tech
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
Praxis Precision Medicines Stock Pre-Market (+12%) : FDA Breakthrough Therapy Designation for Ulixacaltamide - Trefis
Praxis Precision Medicines Stock Surges: What Drives the Wave? - StocksToTrade
Why Praxis Precision Medicines Stock Popped Today - Finviz
Why Praxis Precision Medicines Stock Popped Today - The Motley Fool
Praxis Precision Medicines: An Unexpected Surge? - timothysykes.com
Nvidia, Tesla, Newmont, DigitalBridge, Praxis Precision, Ultragenyx, and More Movers - Barron's
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG By Investing.com - Investing.com South Africa
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation By Investing.com - Investing.com South Africa
Praxis Precision Medicines Soars on FDA Breakthrough Therapy Designation - GuruFocus
Why Is Praxis Precision Medicines Stock Soaring Monday?Praxis Precision Medicine (NASDAQ:PRAX) - Benzinga
Praxis Precision (PRAX) Soars 14.7% on Market Uptick - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month HighTime to Buy? - MarketBeat
Praxis Precision Medicines stock jumps after FDA grants breakthrough therapy designation - Investing.com
Praxis Precision Medicines (PRAX) Surges on FDA Breakthrough Des - GuruFocus
Jefferies reiterates Buy rating on Praxis Precision Medicines stock, cites FDA breakthrough designation - Investing.com UK
Why did Praxis Precision stock surge 12% pre-market today? - MSN
Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday - Benzinga
PRAX Stock Gains as FDA Grants Breakthrough Therapy Status to Ul - GuruFocus
Why Did Praxis Precision Stock Surge 12% Pre-Market Today? - Asianet Newsable
Praxis Precision Medicines stock soars after FDA grants Breakthrough status - Investing.com
Praxis Precision Medicines stock soars after FDA grants Breakthrough status By Investing.com - Investing.com South Africa
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide By Investing.com - Investing.com Nigeria
Praxis Precision Medicines receives FDA breakthrough designation for ulixacaltamide - Investing.com
PRAX Stock Rises 13% in Premarket Trading - GuruFocus
PRAX Receives FDA Breakthrough Therapy Designation for Ulixacalt - GuruFocus
Praxis Wins FDA Breakthrough Status for Ulixacaltamide - TipRanks
Praxis Precision Medicines Receives Breakthrough Therapy Designation from FDA for Ulixacaltamide in Essential Tremor Treatment - Quiver Quantitative
Praxis Precision Medicines Receives Breakthrough Therapy Designation - TradingView — Track All Markets
FDA fast-tracks potential new treatment for people with essential tremor - Stock Titan
Praxis Precision Medicines stock price target raised to $843 from $507 at BTIG - Investing.com
BTIG Raises Price Target for PRAX to $843, Maintains Buy Rating - GuruFocus
Nvidia, Tesla, DigitalBridge, Newmont, Praxis Precision, Ultragenyx, and More Movers - Barron's
Praxis Precision Medicines Earnings Notes - Trefis
FDA-Endorsed Elsunersen Trial Redesign Could Be A Game Changer For Praxis Precision Medicines (PRAX) - Sahm
Congress Asset Management Co. Makes New Investment in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) price target increased by 38.02% to 410.52 - MSN
Praxis Precision Medicines stock hits 52-week high at 283.04 USD - Investing.com Nigeria
Praxis Precision Medicines (NASDAQ:PRAX) Hits New 52-Week HighWhat's Next? - MarketBeat
Medical Stocks To Follow NowDecember 5th - MarketBeat
Aug Wrap: Why Praxis Precision Medicines Inc. stock could be next big winnerMarket Risk Analysis & Fast Entry High Yield Tips - Улправда
Praxis Precision Medicines (PRAX) Price Target Increased by 38.02% to 410.52 - Nasdaq
Assenagon Asset Management S.A. Has $21.72 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
What dividend safety score for Praxis Precision Medicines Inc. stock2025 Earnings Impact & Free Community Consensus Stock Picks - Улправда
Can Praxis Precision Medicines Inc. stock continue upward trendChart Signals & Daily Growth Stock Investment Tips - ulpravda.ru
Why Praxis Precision Medicines Inc. stock appeals to dividend seekersTrade Performance Summary & High Conviction Trade Alerts - Улправда
Can Praxis Precision Medicines Inc. stock beat market expectations this quarterDollar Strength & Advanced Technical Analysis Signals - DonanımHaber
0.23%
0.08%
大文字化:
|
ボリューム (24 時間):